Newsroom

LATEST PUBLICATIONS

ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia

2026-07-09T17:06:05-07:00June 3rd, 2026|

NGS-based MRD monitoring in mature B-cell and plasma cell malignancies

2026-07-09T17:08:21-07:00May 28th, 2026|

T-cell receptor gamma (TRG) diversity predicts peripheral blood involvement in primary cutaneous T-cell lymphoma

2026-07-09T17:12:44-07:00March 5th, 2026|

Ultrasensitive next-generation sequencing-based clonality assay for disease monitoring in B-cell acute lymphoblastic leukaemia

2026-07-07T11:50:22-07:00February 20th, 2026|

Measurable Residual Disease detection in acute lymphoblastic leukaemia – comparison between targeted NGS and ASO-qPCR

2026-07-09T17:00:41-07:00January 23rd, 2026|

Invivoscribe Announces the PrepQuant^TM System, an Integrated Sample Preparation Platform that Standardizes and Streamlines Pre-Analytical Workflows

2026-07-07T11:48:53-07:00April 15th, 2026|

Invivoscribe Expands IVDR Portfolio with IdentiClone Dx IGH Assay Certification

2026-03-25T23:07:06-07:00March 25th, 2026|

Invivoscribe Launches LeukoStratKMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide

2026-02-05T14:09:13-08:00February 4th, 2026|

Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial

2026-03-09T18:04:28-07:00July 7th, 2025|

LabPMM Receives New York State Approval for the NPM1 MRD Assay – Informing Therapy and Accelerating Targeted Trials

2026-03-09T18:40:09-07:00June 17th, 2025|

115th The Annual meeting of the Japanese Society of Pathology

Apr 16 – 18, 2026
Sapporo, Japan
Attending

AACR

Apr 17–22, 2026
San Diego, CA
Exhibiting
Visit Conference Website

BSH 2026

Apr 19-21, 2026
Liverpool, UK
Attending
Visit Conference Website

2nd EHA-SWG Scientific Meeting on MDS/MPN/AML: Commonalities and Differences of Myeloid Neoplasms

Apr 30–May 2, 2026
Ljubljana, Slovenia
Attending
Visit Conference Website

TRI-CON 2026

May 4-5, 2026
San Francisco, CA
Attending
Visit Conference Website

Newsroom

Newsroom

LATEST PUBLICATIONS

ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia

NGS-based MRD monitoring in mature B-cell and plasma cell malignancies

T-cell receptor gamma (TRG) diversity predicts peripheral blood involvement in primary cutaneous T-cell lymphoma

Ultrasensitive next-generation sequencing-based clonality assay for disease monitoring in B-cell acute lymphoblastic leukaemia

Measurable Residual Disease detection in acute lymphoblastic leukaemia – comparison between targeted NGS and ASO-qPCR

LATEST PRESS

Invivoscribe Announces the PrepQuant^TM System, an Integrated Sample Preparation Platform that Standardizes and Streamlines Pre-Analytical Workflows

Invivoscribe Expands IVDR Portfolio with IdentiClone Dx IGH Assay Certification

Invivoscribe Launches LeukoStratKMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide

Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial

LabPMM Receives New York State Approval for the NPM1 MRD Assay – Informing Therapy and Accelerating Targeted Trials

CONFERENCES

115th The Annual meeting of the Japanese Society of Pathology

AACR

BSH 2026

2nd EHA-SWG Scientific Meeting on MDS/MPN/AML: Commonalities and Differences of Myeloid Neoplasms

TRI-CON 2026

Global Search

SEARCH BY KEYWORD

Global Search

SEARCH BY KEYWORD

Looking for Product Documents?
Try our New Document Search Feature ⟶

Looking for Product Documents?
Try our New Document Search Feature ⟶